Differential neuro-immune patterns in two clinically relevant murine models of multiple sclerosis

Krista D. DiSano¹, Michael R. Linzey¹,², Darlene B. Royce¹, Andrew R. Pachner¹ and Francesca Gilli¹*

Abstract

Background: The mechanisms driving multiple sclerosis (MS), the most common cause of non-traumatic disability in young adults, remain unknown despite extensive research. Especially puzzling are the underlying molecular processes behind the two major disease patterns of MS: relapsing-remitting and progressive. The relapsing-remitting course is exemplified by acute inflammatory attacks, whereas progressive MS is characterized by neurodegeneration on a background of mild-moderate inflammation. The molecular and cellular features differentiating the two patterns are still unclear, and the role of inflammation during progressive disease is a subject of active debate.

Methods: We performed a comprehensive analysis of the intrathecal inflammation in two clinically distinct mouse models of MS: the PLP₁₃₉₋₁₅₁-induced relapsing experimental autoimmune encephalomyelitis (R-EAE) and the chronic progressive, Theiler’s murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD). Microarray technology was first used to examine global gene expression changes in the spinal cord. Inflammation in the spinal cord was further assessed by immunohistochemical image analysis and flow cytometry. Levels of serum and cerebrospinal fluid (CSF) immunoglobulin (Ig) isotypes and chemokines were quantitated using Luminex Multiplex technology, whereas a capture ELISA was used to measure serum and CSF albumin levels. Finally, an intrathecal Ig synthesis index was established with the ratio of CSF and serum test results corrected as a ratio of their albumin concentrations.

Results: Microarray analysis identified an enrichment of B cell- and Ig-related genes upregulated in TMEV-IDD mice. We also demonstrated an increased level of intrathecal Ig synthesis as well as a marked infiltration of late differentiated B cells, including antibody secreting cells (ASC), in the spinal cord of TMEV-IDD, but not R-EAE mice. An intact blood-brain barrier in TMEV-IDD mice along with higher CSF levels of CXCL13, CXCL12, and CCL19 provides evidence for an intrathecal synthesis of chemokines mediating B cell localization to the central nervous system (CNS).

Conclusions: Overall, these findings, showing increased concentrations of intrathecally produced Igs, substantial infiltration of ASC, and the presence of B cell supporting chemokines in the CNS of TMEV-IDD mice, but not R-EAE mice, suggest a potentially important role for Igs and ASC in the chronic progressive phase of demyelinating diseases.

Keywords: Multiple sclerosis, Immunoglobulins, B cells, EAE, TMEV-IDD

* Correspondence: Francesca.Gilli@dartmouth.edu

¹Department of Neurology, Dartmouth Hitchcock Medical Center and Geisel School of Medicine, One Medical Center Drive, Lebanon, NH 03756, USA

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS), which causes demyelination, axonal loss, and progressive disability. The cause of MS is unknown, but one hypothesis is that overactivity of both the innate and adaptive arms of the immune system may be involved in the activation of self-reactive or cross-reactive immune cells to antigens associated with the myelin sheath and oligodendrocytes [1–4]. CD4+ T helper 1 (Th1) and Th17 cells, in particular, have been implicated in MS disease pathogenesis, but a variety of other cell types such as CD8+ T cells, B cells, monocytes, neutrophils, macrophages, and microglia have been suggested to be involved both outside of and within the CNS [5–10]. Notably, recent success with B cell depletion therapies has revitalized efforts to understand the pathogenic role of B cells in MS [11, 12].

There are two main disease patterns of MS: relapsing-remitting and progressive [13]. The relapsing-remitting disease course is characterized by clearly defined clinical exacerbations associated with the development of focal inflammatory lesions in the CNS. In contrast, in the chronic progressive course, there is increasing neurologic dysfunction thought to reflect ongoing neurodegenerative processes. To date, the molecular and cellular features differentiating the two patterns are unclear, and the role of inflammation during progressive disease is a subject of active debate.

Mouse models of human MS are helpful in identifying potential pathogenic mechanisms of the disease and its different stages. These MS models were established according to the various hypotheses of the pathogenesis of MS and are aimed at reproducing the clinical signs of MS as far as possible. The two most commonly studied animal models of MS are (1) the autoimmune-induced experimental allergic/autoimmune encephalomyelitis (EAE) [14] and (2) the virally-induced chronic Theiler’s murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD) [15, 16].

EAE is a well established and widely used model of MS, which involves using defined myelin antigens to induce an encephalitogenic immune response. Different manifestations characterize the disease, depending on the antigen used to induce EAE and the rodent strain. In the SJL mouse strain, for example, EAE is usually induced by immunization with a myelin protolipid protein peptide (PLP139–151) or the adoptive transfer of PLP-specific CD4+ T cells into syngeneic recipients [16, 17]. PLP-induced EAE most strongly resembles the relapsing-remitting form of MS (R-EAE), thus representing a valuable model to study the development of relapses and acute inflammation.

TMEV-IDD is another inflammatory model of MS. Different from R-EAE, TMEV-IDD results from a chronic virus infection in the CNS, associated with significant intrathecal antibody production [18–20]. Overall, the TMEV-IDD model features a chronic progressive disease course that lasts for the entire lifespan in susceptible SJL mice [21]. Several features of progressive MS, including the role and significance of axonal injury and repair [22, 23], the partial independence of disability from demyelination [24], and the importance of remyelination [25], have all been demonstrated in this model. The validity of a viral model of MS is also supported by epidemiological evidence that suggests the possibility that a virus may play a role in or even be an etiologic factor for the development of MS [26, 27]. Finally, TMEV-IDD has been widely used to demonstrate mechanisms by which viral infection may contribute to the generation of a heightened immune response, leading to chronic inflammation in the CNS and neurodegeneration.

Although both R-EAE and TMEV-IDD have significantly advanced our understanding of MS and have shed light on some mechanisms underlying relapses and progression in MS, there is an almost total lack of comparative studies between the two animal models. Exploring both similarities and differences between R-EAE and TMEV-IDD, i.e., a relapsing-remitting and a progressive model of MS, may lead to a better understanding of the pathological processes leading to a relapsing-remitting clinical course rather than a progressive disease course.

Materials and methods
Animal models of MS
The experiments consisted of the analysis of four different experimental groups of SJL/J mice: TMEV-IDD, i.e., TMEV-infected SJL/J mice; R-EAE, i.e., PLP-immunized SJL/J mice; sham-treated TMEV-IDD age-matched SJL/J controls; and sham-treated R-EAE age-matched SJL/J controls.

SJL mice were all purchased from The Jackson Laboratory (Bar Harbor, ME) to reduce variability. Mice were maintained on standard laboratory chow and water ad libitum, and standard clinical assessments like weight loss and clinical grading of disease were regularly performed over the follow-up.

Induction of TMEV-IDD
TMEV-IDD mimics some of the pathological and clinical features observed in patients with a progressive form of the disease [21]. TMEV-IDD was induced by injecting 2 million plaque-forming units (PFU) of TMEV, strain BeAn, into the right cerebral hemisphere of 6-week old female SJL/J mice. Mice were first anesthetized with isoflurane and inoculated by free-hand injection in a 30-μL final volume. PFU were determined by a cytopathic effect assay (CPE). Blood from each experimental and control mouse at days 30 and 90 post-infection (p.i)
was collected from the retro-orbital plexus of anesthetized mice; serum was isolated and stored at −80 °C. Neurological disability was assessed weekly using the Rotamex Rotarod instrument (Columbus Instruments; Columbus, OH) as previously described (Additional file 1: Table S1) [28]. Mice were necropsied around day 120 p.i., or earlier if their severe neurological disability endangered their life (Additional file 1: Table S1). Necropsy techniques, including anesthesia, intracranial injection, perfusion with phosphate-buffered saline (PBS), and the collection of blood, cerebrospinal fluid (CSF), and other tissues such as spinal cord and brain, were performed as previously described [19, 29].

Virus persistence in the CNS is necessary to develop the chronic progressive demyelinating disease, which is consistently induced in 90% of the infected mice [16]. Therefore, in our analyses, we only included mice effectively infected with TMEV. Effective infection was proven by demonstrating viral infection of the spinal cord at necropsy by real-time reverse transcription quantitative PCR (RT-qPCR) for TMEV mRNA [30, 31] and anti-TMEV antibody in serum by ELISA [31, 32]. Levels of serum anti-TMEV antibody were tested at 30, 90, and 120 days p.i to further confirm viral persistence.

**Induction of myelin PLP-induced R-EAE**

The PLP peptide-induced R-EAE model in SJL/J mice was chosen because it represents a well-suited tool to experimentally address mechanisms that cause the relapsing autoimmune pathology of the CNS in MS [16]. R-EAE was induced in 8-week-old SJL/J female mice by immunization with PLP139-151 peptide injection in complete Freund’s adjuvant (CFA) containing 1 mg/mL Mycobacterium tuberculosis. Mice were immunized according to a standard protocol using the Hooke Kit™ (Hooke Labs, Lawrence, MA, USA), which contains 200 µg myelin proteolipid protein (PLP139−151) in 200 µL CFA. The emulsion was injected subcutaneously at 4 sites on the back, followed by an intraperitoneal injection of 600 ng of PTx in 100 µL of PBS. Mice were scored blindly and daily from day 7 post-immunization. R-EAE disease was scored using a 5-point grading with 0 for no clinical disease, 1 for tail weakness, 2 for paraparesis (incomplete paralysis of one or two hindlimbs), 3 for paraplegia (complete paralysis of one or two hindlimbs), 4 for paraplegia with forelimb weakness or paralysis, and 5 for moribund or dead animals (Additional file 1: Table S1) [16]. R-EAE mice were sacrificed at the peak of disease severity (around day 15 post-immunization) or when presenting a clinical score ≥ 3 as per our IACUC protocol (Additional file 1: Table S1). Techniques used in the necropsies were performed as described above.

**Control mice**

Control mice in these experiments were included carefully to reflect differences between R-EAE and TMEV-IDD, taking into account differences with respect to age at induction and age at maximal disease. According to previous studies [16], the best age for induction of R-EAE in mice is 8 to 12 weeks, whereas TMEV-IDD development is expected to be most prevalent in mice infected at 6 to 7 weeks. Typically, TMEV-infected mice begin to show signs of clinical disease between 30 and 40 days p.i and develop progressive disability over an average of 120 days p.i., i.e., at ~24 weeks of age. Conversely, R-EAE mice experience their first relapse much earlier, with the most intense symptoms peaking around day 15 post-immunization, i.e., at ~10 weeks of age. This age bias represents a commonality between the two mouse models and human disease, as progressive forms of MS affect, on average, older people compared to relapsing MS. On the other hand, the age-related changes of the immune system may represent a significant confounding factor for biological analyses. Hence, in the present work, age-related bias was specifically addressed by adding two different control groups, i.e., 10 weeks old and 24 weeks old mice, to be compared to their respective age-matched experimental group, i.e., R-EAE and TMEV-IDD, respectively. Each pairwise comparison between the control group and its respective age-matched experimental group was analyzed to identify unique patterns independent of age-related effects. Eight weeks old and 6 weeks old SJL/J mice were sham-treated with equal volumes of PBS and followed over time in parallel to the respective experimental groups, i.e., R-EAE and TMEV-IDD, respectively (Additional file 1: Table S1).

**Total RNA extraction from spinal cord tissues**

Total RNA was extracted from dissected snap-frozen lumbar and sacral portions of the spinal cords with TRIzol® reagent (Ambion, Austin, TX), according to the manufacturer’s protocol. RNA was precipitated from the aqueous phase by addition of isopropanol, washed with ethanol and solubilized for final storage at ~80 °C until further use. RNA concentration and purity were assessed by spectrophotometry (NanoDrop ND1000; NanoDrop Technologies, DE). For microarray analyses, RNA integrity was further evaluated using the Agilent 2100 Bioanalyzer and its lab-on-a-chip platform technology (Agilent Technologies UK Ltd, West Lothian, UK).

**Microarray analysis of gene expression in spinal cord tissues**

Microarray analysis was performed with the Illumina MouseWGE6 BeadChip (Illumina, London, UK). All RNA samples were analyzed on the same day under identical conditions. RNA samples were prepared for
array analysis using the Illumina TotalPrep-96 RNA Amplification Kit, following the manufacturer’s instructions (Ambion/Applied Biosystems, Warrington, UK). First and second strand cDNA was synthesized from 0.1 to 0.5 µg of total RNA and labeled with biotin. The biotin-labeled cRNA was applied to the arrays using the whole-genome gene expression direct hybridization assay system from Illumina. Finally, the BeadChips was scanned using the Illumina BeadArray Reader. The data was extracted using BeadStudio 3.2 (Illumina, London, UK).

RT-qPCR analysis of gene expression in spinal cord tissues
Chitinase-3-like protein 4 (Chi3l4), chemokine (C-X-C motif) ligand 13 (CXCL13), and immunoglobulin-G1 (IgG1) mRNA quantitation were performed using RT-qPCR analysis of cDNA. Briefly, total RNA (50 ng/µL) was reverse transcribed with the qScript™ cDNA SuperMix (QuantaBio, Gaithersburg, MD). cDNA was then used as a template for the RT-qPCR analysis based on the 5′ nuclease assay with the PerfeCTa qPCR FastMix II ROX (QuantaBio, Gaithersburg, MD). Mouse glyceraldehyde phosphate dehydrogenase (GAPDH) was used as a reference gene. TaqMan Gene Expression Assays (ThermoFisher Scientific, Waltham, MA) were used as primers and probes for Chi3l4, CXCL13, and GAPDH, whereas custom primers and probes were used for the amplification of IgG1 [19]. The relative mRNA expression level of each target gene was analyzed by the 2−ΔCt method, in which ΔCt is (Ct_target−CtGAPDH) [33].

Protein measurements by ELISAs
Soluble proteins were extracted from spinal cord samples following the TRIzol® (Ambion, Austin, TX) method for protein isolation during RNA isolation. Proteins were precipitated from the organic phase with ethanol and isopropanol, washed with ethanol and solubilized, for final storage at −80°C until further use.

We measured the total amount of protein extracted with the Pierce BCA Protein Assay Kit (ThermoFisher Scientific, Waltham, MA). Specific proteins levels were then measured by using commercially available ELISAs for the quantification of Chi3l4 (LSBio, Seattle, WA) and CXCL13 (BioLegend, San Diego, CA). Values were normalized to the total amount of protein contained in each sample.

Albumin was measured in serum and CSF specimens with a commercial Mouse Albumin capture ELISA kit (Novus Biologicals, Littleton, CO) using the protocol suggested by the manufacturer.

Protein measurements by Luminex
A magnetic bead-based approach was used to measure a broad panel of proteins in matched serum and CSF specimens, including the immunoglobulin isotyping panel and reagents kit (MilliPlex MAP Mouse Immunoglobulin Isotyping Magnetic Bead Panel, EMD Millipore, Burlington, MA) and the chemokine Luminex kit (Bio-Plex Pro™ Mouse Chemokine Panel, BioRad, Cambridge, MA). To differentiate blood- vs. CNS-derived Igs in the CSF, we used albumin quotient (Qalbumin) and Ig index. Ig indices were calculated as 

\[ \text{Q Ig/Qalbumin} = \frac{[\text{CSF/serum Ig}] / [\text{CSF/serum albumin}]}{\text{Ig index}}. \]

Immunophenotyping of spinal cord-infiltrating B cells through flow cytometry
For B cell analysis via flow cytometry, spinal cord-derived mononuclear cells were isolated from individual spinal cords utilizing collagenase type I (1 mg/mL) and DNase I (100 U/mL) (Worthington Biochemical Corporation, Lakewood, NJ) as previously described [34]. Cells were recovered from the 30/70% Percoll interface and resuspended in fluorescence-activated cell sorter (FACS) buffer for flow cytometry staining. Before staining, cells were incubated with fixable viability stain 780 APC-Cy7 (BD Biosciences, San Jose, CA) and washed in FACS buffer. Cells were then incubated with FACS buffer supplemented with 1% mouse serum and 0.5 µL per 106 cells rat anti-mouse FcyIII/II mAb (2.4G2; BD Bioscience, San Jose, CA) to prevent non-specific staining. Expression of cell surface markers was assessed by staining with antibodies specific for CD45 (30-F11; PerCP-Cy5.5), CD19 (1D3; PE-CF594), IgD (11-26; APC), and IgM (eB131-15F9; PE) (BD Biosciences, San Jose, CA). Cells were analyzed using a Beckman Coulter Gallios flow cytometer (BD Biosciences, San Jose, CA) and FlowJo version 9.7.6 software (Tree Star, Ashland, OR). Cell numbers were calculated based on live cell yields and percentages of gated live cells. Dead cells were excluded using a fixable viability stain and comprised less than 10% of isolated cells. Doublets were excluded based on FSC-Area and FSC-Height.

Immunohistochemical detection of B cells in spinal cord tissue
Spinal cords from PBS-perfused R-EAE or TMEV-IDD mice were fixed in 10% neutral buffered formalin for 24–48 h. Spinal cords were segmented into cervical, upper thoracic, and lower thoracic regions and embedded in paraffin. Tissue blocks were then surface decalcified using nitric acid bone decalcifier (StatLab medical products, McKinney, TX) for 5–10 min, washed, and cut in sections of 4 µm thickness. We optimized a deparaffinization and rehydration protocol performing two xylene 10-min washes followed by two 10-min 100% ethanol washes, and sequential 5-min washes of 95% ethanol, 70% ethanol, and 50% ethanol. Following PBS washes, antigen retrieval was performed at 95°C for 30 min in Tris-EDTA 0.1% Tween 20 buffer and then cooled, washed in PBS, and blocked with 5% bovine serum.
albumin (BSA) and 10% goat serum. After blocking, spinal cord sections were incubated with rat IgG anti-mouse B220 mAb (BD Biosciences, San Jose, CA) or goat anti-mouse IgG (subclasses 1, 2a, 2b, 3) conjugated with Alexa Fluor 594 (Jackson Laboratories, Sacramento, CA), and rabbit IgG anti-mouse CD3 SP7 clone polyclonal Ab (Abcam, Cambridge, MA). B220 and CD3 primary antibodies were detected using secondary Alexa Fluor 594 goat anti-rat and Alexa Flour 488 goat anti-rabbit antibody (Life Technologies, Grand Island, NY). Sections were mounted with Vectashield Hardset reagent with 4′,6-diamidino-2-phenylindole (DAPI) (Vector Labs, Burlingame, CA) and examined using a Zeiss LSM 800 confocal microscope with Airyscan (Zeiss, Oberkochen, Germany). Z-series images were collected every 0.2 μm covering a tissue depth of 2–3 μm. Projected images using ImageJ software (NIH, http://rsbweb.nih.gov/ij) were supplemented with the FIJI plugin set (http://fiji.sc).

**Statistical analyses**

**Microarray statistical analysis**

Statistical analysis of microarray data was performed using BRB-Array Tools version 4.2.1 (NIH, https://brb.nci.nih.gov/BRB-ArrayTools). Four biological replicate samples per experimental group were analyzed. Variance stabilizing transformation and robust spline normalization was applied to raw intensity data, which was then filtered to remove non-detectable spots as determined by Illumina Software.

The goal of the statistical analysis was to identify the subset of genes that were differentially expressed in the spinal cord between sham controls vs. R-EAE or TMEV-IDD mice. To accomplish this goal, we employed both univariate and multivariate statistical and computational methods in a supervised manner. For the univariate analysis, we used the unpaired t test, the non-parametric Wilcoxon rank-sum test, and the statistical analysis of microarrays (SAM) test. We then constructed generalized Venn diagrams of the statistical results using the VennMaster software package and selected differentially expressed genes as those that were considered significant by two or more of the univariate statistics. Hierarchical cluster analysis of significant genes was performed using a variety of distance metrics (Pearson, Euclidean, Manhattan, and Maximum) and clustering methods (Average, Single, Complete) for characterizing the correlations structure of the genes and the samples. Heat maps were used to visualize the clustering results. We then carried out a supervised multivariate analysis of the selected genes using decision trees (DT). The advantage of using DT is that the models can be represented as simple IF-THEN rules (e.g., IF gene 1 < 10 and gene 2 > 15 THEN disease) that are easy to interpret. The predictive ability of our multivariate models was assessed using leave-one-out cross-validation (LOOCV).

The LOOCV procedure provides unbiased estimates of the prediction error or testing accuracy of the models. All analyses were carried out using the open-source R statistical package (https://www.r-project.org) and the open-source Weka data mining software package (https://www.cs.waikato.ac.nz/ml/weka/).

To address the age-related bias, we analyzed two different control groups (i.e., 10-week-old and 24-week-old mice) compared to age-matched experimental groups, i.e., R-EAE and TMEV-IDD, respectively. Each pairwise comparison between the control group and the respective age-matched experimental group was then analyzed to identify unique expression patterns independent of age-related effects.

To address the problem of small sample size, i.e., n = 4 samples per group, we incorporated information from diverse sources to analyze the microarray data to improve the predictability of significant genes. We used a transformed dataset, including statistical parameters, literature mining, and gene ontology data. The proposed analysis method allowed the transformation of a high dimensional microarray data into a concise and significant dataset.

To gain insight into the biological significance of the different sub-clusters of genes, we evaluated enriched functional annotation categories (Gene Ontology—GO) for the target genes using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) bioinformatics tools (https://david.ncifcrf.gov) according to their enrichment p value.

**Other statistical analyses**

Further data generated within the present study, e.g., RT-qPCR, ELISAs, and Luminex data, were analyzed using both parametric and non-parametric statistical tests, based on the specific experimental condition. Data were compared by Student’s t test, i.e., Mann-Whitney U test, Wilcoxon test, Kruskal-Wallis test, and Friedman test. Those analyses were performed using Prism version 7.00 for Mac (GraphPad, San Diego CA), and all reported p values were based on two-tailed statistical tests, with a significant level of 0.05.

**Results**

**Differential spinal cord gene expression in R-EAE and TMEV-IDD mice**

For each mouse model, gene expression in the spinal cord of treated and control animals was compared with each other (Additional file 1: Table S1). This design yielded two main comparisons: (1) R-EAE vs. age-matched controls and (2) TMEV-IDD vs. age-matched controls (Additional file 2: Table S2). We focused on the more highly altered genes, filtering for a fold change ≥2 and a p value < 0.05. This analysis reduced the
TMEV-IDD list to 526 probes and the R-EAE list to 1357 probes. The following union of the two lists led to 1494 significantly different probes, i.e., at least 2-fold up- or downregulated between control and treated mice, in at least 1 of the 2 groups.

Next, to examine differences in altered genes between TMEV-IDD and R-EAE, we clustered the 1494 probes. We identified four sub-clusters (Fig. 1, Additional file 3: Table S3) that showed the most differential expression patterns between TMEV-IDD and R-EAE. Sub-cluster #1 contains genes that are unchanged in TMEV-IDD but are downregulated in R-EAE. In sub-cluster #2, genes are upregulated in TMEV-IDD only. Sub-cluster #3 includes genes upregulated in both TMEV-IDD and R-EAE, whereas in sub-cluster #4, genes are upregulated in R-EAE only.

In sub-cluster #1, a significant change in expression was seen in 51 known genes and 3 predicted genes, when R-EAE mice were compared with their age-matched control mice. Overall, we found a total of 9 GO terms including “myelination” ($p = 0.008$), “brain development” ($p = 0.01$), and “axonogenesis” ($p = 0.02$) (Additional file 4: Table S4).

In sub-cluster #2, a significant change in expression was observed in 50 genes and 27 predicted genes, when TMEV-IDD mice were compared with their age-matched control mice. A total of 32 GO terms, including “positive regulation of B cell activation” ($p < 0.0001$), “B cell receptor signaling pathway” ($p < 0.0001$), “complement activation-classical pathway” ($p < 0.0001$), and “innate immune response” ($p = 0.015$), were significantly enriched in the set of specific TMEV-IDD upregulated genes (Additional file 4: Table S4). More specifically, many Ig-related genes such as IgK-C, Igh-VJ558, IgL-V1, and Igh-4 were upregulated in TMEV-IDD only. CXCL13, a major chemoattractant for B cells, was also overexpressed in the spinal cord of TMEV-IDD mice.

The genes upregulated in R-EAE but not in TMEV-IDD in sub-cluster #4 were 107 plus 7 predicted genes. A total of 86 GO terms, including “chemotaxis” ($p < 0.0001$), “leukocyte migration” ($p = 0.0006$), “cellular response to interleukin-1” ($p < 0.0001$), “T cell differentiation involved in immune response” ($p = 0.019$), “T helper cell differentiation” ($p = 0.024$), and “adaptive immune response” ($p = 0.030$), were significantly enriched in this set of genes (Additional file 4: Table S4). Among the others, the chitinase family (Chi3l4, Chi3l3, Chi3l1) was found overexpressed in R-EAE and not in TMEV-IDD.

We also determined GO terms that were enriched in sub-cluster #3. A total of 437 GO terms, including “antigen processing and presentation” ($p < 0.0001$), “Myd88-dependent toll-like receptor signaling pathway” ($p < 0.0001$), “microglial cell activation” ($p < 0.0001$), “response to interferon-beta” ($p < 0.0001$), “Toll-like receptors signaling pathways” (TLR7, TLR3, TLR4, TLR9, all $p < 0.0001$), and “astrocytes development” ($p = 0.016$), were significantly enriched in the set of genes upregulated in both R-EAE and TMEV-IDD (Additional file 4: Table S4).

**Gene and protein expression confirmatory analysis**

RT-qPCR was performed for two selected genes listed within the top ten upregulated genes in either R-EAE (Chi3l4) or TMEV-IDD (CXCL13) mice (Additional file 1: Table S1). For each gene, the increased expression initially suggested by microarray analysis was confirmed (Fig. 2a, b). CXCL13 mRNA levels were significantly higher in TMEV-IDD mice compared to R-EAE and sham mice ($p < 0.0001$) (Fig. 2a). Conversely, Chi3l4 gene expression was higher in R-EAE mice compared to both TMEV-IDD and sham mice ($p = 0.031$) (Fig. 2b).

CXCL13 and Chi3l4 ELISAs were then performed to quantitate protein levels, using spinal cord lysates as proteins’ source. As shown in Figure 2d and e, significant differences were observed in both CXCL13
Production of IgG within the CNS was measured by using both a RT-qPCR assay for IgG1 mRNA and a Luminex assay for total IgG proteins in the spinal cord of TMEV-IDD and R-EAE mice (Additional file 1: Table S1). Levels of IgG1 mRNA in the spinal cord were significantly higher in TMEV-IDD mice compared with R-EAE mice \( (p < 0.0001) \) (Fig. 2c). In accordance, higher levels of total IgG were observed in the spinal cord of TMEV-IDD mice relative to R-EAE mice, although the difference was not significant \( (p = \text{NS}) \) (Fig. 2f).

### Phenotype and localization of B cells in the spinal cord of TMEV-IDD vs. R-EAE mice

Upregulated Ig- and B cell-related genes in TMEV-IDD suggested predominant B cell presence in CNS tissue during TMEV-IDD compared to R-EAE. Thus, we next sought to analyze alterations in B cell populations in the spinal cords of TMEV-IDD and R-EAE mice utilizing flow cytometry (Additional file 1: Table S1). Levels of IgG1 mRNA in the spinal cord were significantly higher in TMEV-IDD mice compared with R-EAE mice \( (p < 0.0001) \) (Fig. 2c). In accordance, higher levels of total IgG were observed in the spinal cord of TMEV-IDD mice relative to R-EAE mice, although the difference was not significant \( (p = \text{NS}) \) (Fig. 2f).

Phenotypic comparison of spinal cord-infiltrating B cells in TMEV-IDD and R-EAE revealed significant differences in infiltrating B cell differentiation phenotype, with more than 80% of B cells in R-EAE spinal cords comprising a naïve/early activated phenotype \( (p < 0.0001) \) (Fig. 3f). In contrast, more than 60% of spinal cord-infiltrating B cells in TMEV-IDD were identified as an isotype-switched ASC/Bmem phenotype \( (p < 0.0001) \).
Fig. 3  B cell accumulation in spinal cords of R-EAE and TMEV-IDD. Total B cells and B cell phenotypes defined by IgD and IgM surface marker expression were identified by flow cytometry in spinal cords from TMEV-IDD mice (n = 22) at day 120 post-infection or R-EAE mice (n = 12) at day 14 post-immunization. 

a Representative plot showing minimal CD45hi infiltrating immune cells among total live cells in sham mice.

b Representative gating strategy of CD45hi CD19+ B cells among total live cells isolated from TMEV-IDD or R-EAE spinal cords. Bar graphs depict mean percentage ± SEM (c) and mean number ± SEM (d) of CD45hi CD19+ B cells in TMEV-IDD or R-EAE spinal cords. 

c Representative smoothed plot discriminating IgD and IgM subsets including 1, IgD+IgM+ naïve/early activated; 2, IgD+IgM+ activated; 3, IgD-IgM+ transitional/unswitched memory or ASC; and 4, IgD-IgM- switched memory/ASC B cells within CD45hi CD19+ cells in TMEV-IDD. 

f Bar graph depicting mean percentages ± SEM of B cell phenotypes discerned by IgD and IgM surface marker expression in TMEV-IDD and R-EAE. Statistical differences between TMEV-IDD and R-EAE spinal cords are indicated as determined by an unpaired t test. Data are representative of 3 independent experiments with 6 to 8 mice per experiments for TMEV-IDD and 2 independent experiments with 6 mice per experiment for R-EAE. ****p < 0.0001
which may downregulate B220 surface expression and thus become undetectable by B220 immunostaining. Thus, spinal cord sections were stained for the B cell marker IgG to assess localization of isotype-switched B cells and confirm minimal isotype-switched B cell accumulation in R-EAE. TMEV-IDD spinal cords revealed widespread parenchymal IgG⁺ B cell infiltration, with aggregation present in the ventral midline and ventral lateral meningeal regions of the spinal cord, often accumulating with CD3⁺ T cells. In contrast, minimal IgG⁺ immunoreactivity was observed in R-EAE spinal cords, with diffuse immunostaining proximal to the ventral midline, likely indicative of IgG leakage as a result of blood-brain barrier (BBB) permeability.

Transudation and intrathecal synthesis of Igs in R-EAE and TMEV-IDD

Multiplex analysis of different Ig subclasses and isotypes in the serum and CSF of individual mice was conducted to further confirm intrathecal antibody production in TMEV-IDD. Significant elevation of all the tested Igs was observed in the CSF of both R-EAE and TMEV-IDD mice when compared to sham controls (all \( p \leq 0.038 \)) (Additional file 1: Table S1). The CSF/serum albumin ratio (\( Q_{\text{albumin}} \)) was then calculated to assess BBB function. We found a significant difference in \( Q_{\text{albumin}} \) (\( p = 0.0132 \)); R-EAE mice showed higher values compared to both TMEV-IDD and sham mice (both \( p \leq 0.021 \)), indicating increased permeability of the BBB in R-EAE, but not in TMEV-IDD (Fig. 6). Additionally, there was no difference in \( Q_{\text{albumin}} \) between TMEV-infected and sham mice (\( p = 0.376 \)), therefore confirming BBB integrity in TMEV-IDD. Similar conclusions resulted from a previous study from our group [20], which showed a lack of any measurable disruption of the BBB for either large or small molecules, as tested with both \( Q_{\text{albumin}} \) and Evans Blue, in chronic TMEV-IDD.

To further discriminate between the passive transfer from the serum and intrathecally produced Igs, we also measured the ratio of Igs in CSF to serum (divided by the \( Q_{\text{albumin}} \) to correct for variance in BBB permeability) as an index of the endogenous production of Igs in the CNS. Indices of all Igs, except for IgG3 and IgM, were significantly increased in TMEV-IDD mice compared to both R-EAE mice also had higher serum CCL19 levels, but the difference was not statistically significant (\( p = 0.16 \)) (Fig. 5f).

B cell-related chemokines in serum and CSF of R-EAE and TMEV-IDD mice

Because microarray analysis, flow cytometry, and immunohistochemistry showed prominent involvement of B cells in TMEV-IDD, and to further understand mechanisms that influence B cell trafficking and accumulation in the CNS, we studied CSF and serum levels of some chemokines involved in B cell trafficking including CCL19, CXCL12, and CXCL13. CSF CCL19, CXCL12, and CXCL13 were all significantly elevated in TMEV-IDD mice as compared to both R-EAE mice and sham controls (all \( p \leq 0.029 \)) (Fig. 5a, c, e) (Additional file 1: Table S1).

Conversely, serum CXCL12 and CXCL13 were increased in R-EAE mice as compared to both TMEV-IDD and sham controls (both \( p \leq 0.0004 \)) (Fig. 5b, d).
Discussion

In the above studies, we have compared two different murine models of MS. TMEV-IDD and R-EAE in the SJL mice are both relevant murine immune-mediated demyelinating models that recapitulate the two main MS disease phenotypes: TMEV-IDD serves as a virus-induced model of chronic progressive MS, whereas R-EAE closely mimics the clinical symptoms of relapsing-remitting MS (RRMS). This work has relevance to biological pathways differentially involved in these two forms of MS.

To determine the cellular and molecular changes associated with the differences in clinical course, a microarray analysis was carried out to identify genes with enriched expression in both models during the peak of their clinical disease, i.e., in the spinal cord of R-EAE mice during the peak of their first relapse as well as of TMEV-IDD mice during the late, chronic stage of their disease. Gene expression datasets from both models were compared to identify common and differential genes and pathways. A vast majority of genes mostly involved in innate/adaptive immunity pathways were similarly upregulated in the two models when compared to age-matched sham controls. However, we also identified three groups of genes that were regulated differently in R-EAE and TMEV-IDD.

The enrichment for genes associated with the regulation of axonogenesis, demyelination, and remyelination in the first gene cluster, i.e., sub-cluster #1, suggests active cycling between demyelination/remyelination and axonal regeneration in the spinal cord of R-EAE mice.
but not in the spinal cord of mice in the later stage of TMEV-IDD. The second gene cluster, i.e., sub-cluster #4, highlights, in R-EAE, a gene set enriched in processes related to adaptive immune responses, particularly T cell recruitment, activation, and differentiation. T cells are known to play a pivotal role in R-EAE as well as RRMS. Increased numbers of T cells are found in both the CNS and the periphery of R-EAE mice as well as in acute CNS lesions and CSF of MS patients during relapses [35, 36]. Therefore, our present data support the contribution of T cells in triggering clinical exacerbations.

The mechanism of CNS damage in MS has long been ascribed only to activated T cells that infiltrate the CNS and cause tissue injury [37]. Over the last decade, however, a significant amount of data has also implicated a dysregulated B cell biology in the pathogenesis of MS [38]. Although the pathogenesis of progressive MS remains unclear, B cells seem to play a significant role in chronic compartmentalized inflammation, likely contributing to disease progression [39]. Moreover, intrathecal Ig synthesis is associated with a worse long-term prognosis, greater disability, and faster MS disease progression [40–43]. Hence, most interesting was the enrichment in the third gene cluster, i.e., genes upregulated in TMEV-IDD as per sub-cluster #2, for genes involved in B cell activation and Ig synthesis. Since the increased expression of this specific gene cluster in TMEV-IDD may associate with dominant B cell presence in the CNS, we also compared alterations in B cell populations in the spinal cords of TMEV-IDD and R-EAE mice. Surprisingly, flow cytometric analysis revealed an increase in spinal cord-infiltrating B cells in both models, although to a lesser extent in R-EAE. This finding, which at first glance seems to contradict our gene expression data, implicates either a discrepancy between gene expression and protein translation or, more likely, phenotypic differences in the infiltrating B cells, underlying enhanced expression of genes involved in B cell activation and Ig production in TMEV-IDD compared to R-EAE. In line with the latter, a phenotypic comparison of the B cells infiltrating the spinal cords of the two models indicated an overall upregulation of markers typically associated with naïve/early activated B cells in R-EAE and with late differentiated B cells including ASC and Bmem in TMEV-IDD. These findings have important implications for functional differences in B cells infiltrating the CNS in R-EAE vs. TMEV-IDD. In R-EAE, a predominance of naïve/activated B cells suggests a possible role in antigen presentation [44–46] and/or pro- and anti-inflammatory cytokine production [47–49] in acute disease, as previously suggested in other acute EAE models. In contrast, during chronic TMEV-IDD, isotype-switched B cells, including Bmem and ASC phenotypes, preferentially accumulate in the CNS. Bmem and ASC, including plasmablasts and plasma cells, can produce pro- and anti-inflammatory cytokines [50–52] and engage in antigen presentation (only plasmablasts and Bmem) [53], while antibody production is unique to ASC. Interestingly, following stimulation, Bmem can rapidly convert into ASC to support ongoing antibody production [54, 55]. Our data thus show that alteration of the infiltrating B cell subsets and/or the Ig production
capacities can be associated with the stage of the disease, i.e., acute and relapsing vs. chronic and progressive disease, eventually predicting disease evolution. B cells late in their differentiation sequence, i.e., plasma cells and Bmem cells, seem to preferentially accumulate in the CNS during a chronic progressive disease rather than during an acute inflammatory event. This concept is in line with previous findings showing that plasma cells and Bmem cells are commonly found in the chronically inflamed CNS [56], driving various chronic inflammatory conditions, including MS. Indeed, similar to what we describe in our experimental models, other authors have reported a trend toward an increase in the number of differentiated B cells in CNS lesions from patients with progressive MS in comparison to those with RRMS [9, 57].

Functionally, the B cell activation-related differences between R-EAE and TMEV-IDD may translate into an enhanced intrathecal antibody synthesis in progressive disease compared to acute relapses. While B cells aggregated to similar CNS regions in the two models, mostly accumulating in the ventral midline and ventral lateral aspects of the spinal cord, only TMEV-IDD exhibited high intrathecal Ig production. Several studies in patients seem to confirm this as an intrathecal synthesis of Igs, for example, is a crucial biological feature of MS, and a growing body of evidence suggests that it correlates with MS disease progression [40, 42, 43]. Moreover, a lack of correlation between CSF IgG levels and acute relapses in MS has been shown, while the intrathecal synthesis of Igs positively correlated with disease progression [41].
It remains unknown whether the B cells found in the CNS mature outside the CNS and then localize to the brain and spinal cord or whether the B cell differentiation occurs within the CNS. An intact BBB in TMEV-IDD mice along with the higher CSF levels of CXCL13, CXCL12, and CCL19 compared to matched serum samples provides evidence for an intrathecal synthesis of these chemokines mediating B cell localization to the CNS. Moreover, high Ig indices suggest antibody production is fostered within the CNS. Overall, these results indicate that the CNS may provide a niche for sustaining B cell responses independent of ongoing peripheral recruitment in progressive disease. In MS, B cell aggregation in the CNS is thought to perpetuate neuro-inflammation through the local generation of pathogenic lymphocytes or autoantibodies [58]. B cell aggregates were found in the meninges of patients with progressive forms of MS and were associated with worse outcomes in patients [59, 60]. These aggregates exhibited some features reminiscent of B cell follicles in lymphoid tissue, including the presence of diverse B cell maturation phenotypes, B cell proliferation, and the presence of a stromal network producing B cell-related chemokines such as CXCL13 and CCL19 [60, 61]. Although we have yet to explore the contribution of B cell follicles in TMEV-IDD, our current studies support the notion that a compartmentalized B cell response occurs in the CNS of TMEV-IDD mice, but not in the CNS of R-EAE.

Conversely, in R-EAE, we observed a significant BBB breakdown, which is known to be a fundamental characteristic of EAE models [62], especially following PTx administration [63]. Concurrently, our results revealed that R-EAE mice had increased levels of CXCL13, CXCL12, and CCL19 in their serum, but not in their CSF. Elevations of these chemokines in the serum are consistent with an ongoing peripheral immune response, including the trafficking of B cells. Along the same line, the albumin quotient correlated with the Ig quotients suggesting that the CSF Ig elevation in these mice is mostly associated with a leaky BBB. These findings in R-EAE point toward ongoing peripheral B cell trafficking and activation that may have relevance to relapses. Similar to what has been previously described in PLP139-151-induced EAE studies in SJL mice [64], guinea pigs [65, 66], and rabbits [67], our data in R-EAE indicate that elevated CNS Ig levels, particularly oligoclonal IgG levels, are likely to be the result of a systemically primed humoral immune response toward a given antigen, without intrathecal Ig production. Although EAE is commonly considered a unique model for MS and as such has been largely used for studying overall MS disease pathogenesis, our findings reinforce the concept that PLP139-151-induced R-EAE in SJL mice mimics only partial aspects of MS, e.g., acute inflammation and relapses, which seem to be independent of intrathecal Ig synthesis, a key biological feature of MS. On the other hand, the intrathecal Ig synthesis observed in TMEV-IDD suggests that this model better mimics chronic inflammation in the CNS and thus progressive disease. Also, our findings in mice support the idea of a correlation between intrathecal Ig synthesis and disease progression in humans with MS. Finally, given that intrathecal Ig synthesis in TMEV-IDD results from the ongoing maintenance of B cells in the CNS compartment driven by a persistent viral infection of the CNS, and in line with previous evidence demonstrating an abnormal accumulation of Epstein-Barr virus (EBV)-infected B cells in the CNS of patients with progressive MS [27], our study provides support for the possible role for infectious agents in MS etiology.

**Conclusions**

Overall, these findings, showing increased concentrations of intrathecally produced Iggs as well as substantial infiltration of ASC in the CNS of TMEV-IDD mice, but not R-EAE mice, suggest a potential causative role for Iggs and ASC in the chronic progressive phase of demyelinating diseases. Although further longitudinal studies in both TMEV-IDD and R-EAE will be necessary to reveal more complex disease patterns and their temporal characteristics, our present findings provide clear insight into the major pathological differences during relapsing and progressive phases of MS. These findings could have important clinical implications, given the current paucity of treatment options for people with progressive MS.

**Additional files**

- **Additional file 1:** Table S1. Clinical and experimental characteristics of mice. Mice information. (DOCX 24 kb)
- **Additional file 2:** Table S2. Gene expression changes in R-EAE (E) and TMEV-IDD (T) versus their respective age-matched controls (Sham_E and Sham_T). Microarray data. (XLSX 2720 kb)
- **Additional file 3:** Table S3. Subclusters of genes/probes showing the most differential expression patterns between TMEV-IDD and R-EAE. Microarray data. (XLSX 111 kb)
- **Additional file 4:** Table S4. Gene ontology enrichment analysis in subcluster #1. Microarray data. (XLSX 29 kb)

**Abbreviations**

- ASC: Antibody secreting cells
- BBB: Blood-brain barrier
- Bmem: Memory B cell
- CCL9: Chemokine (C-C motif) ligand 19
- CPE: Cytopathic effect assay
- CSF: Cerebrospinal fluid
- CXCL13/12: Chemokine (C-X-C motif) ligand 13/12
- CXCL13: Chemokine (C-X-C motif) ligand 13/12
- CFA: Complete Freund’s adjuvant
- Chi3l4: Chitinase-3-like protein 4
- CNS: Central nervous system
- CPE: Cytopathic effect assay
- p.i: Post-infection
- DT: Decision trees
- EBV: Epstein-Barr virus
- FACS: Fluorescence-activated cell sorter
- GAPDH: Glyceraldehyde phosphate dehydrogenase
- GO: Gene ontology
- IACUC: Institutional Animal Care and Use Committee
- Ig: Immunoglobulin
- LOOCV: Leave-one-out cross-validation
- MS: Multiple Sclerosis
- PBS: Phosphate-buffered saline
- PFU: Plaque-forming units
- PLP: Proteolipid protein peptide
- PTx: Pertussis toxin
- Q albumin: Albumin quotient
- R-EAE: Relapsing experimental allergic encephalomyelitis
RRMS: Relapsing-remitting MS; RT-qPCR: Real-time reverse transcription quantitative PCR; SAM: Statistical analysis of microarrays; Th1 T helper; TMEV-IDD: Theiler's murine encephalomyelitis virus-induced demyelinating disease

Acknowledgements
The authors thank the staff of the Center for Comparative Medicine and Research (CCMR) at Dartmouth College for their expert care of the mice used for this study. The authors also acknowledge the Norris Cotton Cancer Center (NCCC) light microscopy shared resource (IPM) supported in part by NCI Cancer Center Support Grant SP30 CA023108-37 and also NIH S10 SIG award S10OD21616 funding the LSM800 confocal. Finally, the authors acknowledge Carol Ringelberg for her technical assistance with the microarray statistical analysis.

Funding
This research was funded by research grants from the Hitchcock Foundation, the Diamond endowment, and the Bornstein Research Fund. The funding body had no role in the design, collection, analysis, and interpretation of data, nor were they involved in the writing of the manuscript and the decision to submit it for publication.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
All authors contributed to the study concept and design and to the data acquisition and analysis. FG, KD, and ARP contributed to drafting the manuscript and figures. All authors read and approved the final manuscript.

Ethics approval
All animal experiments were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Dartmouth College (#00002101 and #00002187).

Consent for publication
Not applicable

Competing interests
FG has received research support from Biogen Idec and Sanofi-Genzyme. ARP has received personal compensation for activities with Biogen Idec, EMD Serono, Novartis, Hoffman-LaRoche, Biogen Idec, EMD Serono, and Sanofi-Aventis. The other authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Neurology, Dartmouth Hitchcock Medical Center and Geisel School of Medicine, One Medical Center Drive, Lebanon, NH 03756, USA.
2Program in Experimental and Molecular Medicine, Dartmouth College, Hanover, NH, USA.

Received: 15 March 2019 Accepted: 6 May 2019
Published online: 22 May 2019

References
1. Bennett JL, Stuve O. Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications. Clin Neuropharmacol. 2009;32:121–32.
2. Hafler DA, Slavik JM, Anderson DE, O’Connor KC, De Jager P, Baecher-Allan C. Multiple sclerosis. Immunol Rev. 2005;204:208–31.
3. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol. 2007;8:913–9.
4. Barnett MH, Primeas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol. 2004;55:458–68.
5. Meirl E, Krumholz M, Hohlfeld R. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol. 2006;59:880–92.
6. Franciotta D, Salvetti M, Lolli F, Serafini B, Aloisi F. B cells and multiple sclerosis. Lancet Neurol. 2008;7:852–8.
7. Denic A, Woolda B, Rodriguez M. CD8(+) T cells in multiple sclerosis. Expert Opin Ther Targets. 2013;17:1053–66.
8. Ravji KS, Yong W. The benefits and detriments of macrophages/microglia in models of multiple sclerosis. Clin Dev Immunol. 2013;2013:948976.
9. Machado-Santos J, Saij E, Troscher AR, Paunovic M, Liblau R, Gabriely G, Bien CG, Bauer J, Lassmann H. The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells. Brain. 2018;141:2066–82.
10. Miller MM, Wang J, Tan Y, Dittel BN. Anti-inflammatory mechanisms of IFN-gamma studied in experimental autoimmune encephalomyelitis reveal neutrophils as a potential target in multiple sclerosis. Front Neuosci. 2015;9:287.
11. Midaglia L, Mora L, Mulero P, Sastre-Garriga J, Montalban X. Rituximab: its efficacy, effectiveness and safety in the treatment of multiple sclerosis. Rev Neurol. 2018;66:25–32.
12. Montalban X, Hauner SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, et al. Orelicizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376:209–20.
13. Dutta R, Trapp BD. Relapsing and progressive forms of multiple sclerosis: insights from pathology. Curr Opin Neurol. 2014;27:271–8.
14. Lovett-Racke AE. Contribution of EAE to understanding and treating multiple sclerosis. J Neuroimmunol. 2017;304:40–2.
15. Pachner AR. Experimental models of multiple sclerosis. Curr Opin Neurol. 2011;24:291–9.
16. McCarthy DP, Richards MH, Miller SD. Mouse models of multiple sclerosis: experimental autoimmune encephalomyelitis and Theiler’s virus-induced demyelinating disease. Methods Mol Biol. 2012;900:381–401.
17. Constantinescu CS, Farooqi N, O’Brien K, Gran B. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol. 2011;164:1079–106.
18. Lipton HL, Gonzalez-Scarano F. Central nervous system immunity in mice infected with Theiler’s virus. I. Local neutralizing antibody response. J Infect Dis. 1978;137:145–51.
19. Pachner AR, Brady J, Narayan K. Antibody-secreting cells in the central nervous system in an animal model of MS: phenotype, association with disability, and in vitro production of antibody. J Neuroimmunol. 2007;190:112–20.
20. Pachner AR, Li L, Laguoff D. Plasma cells in the central nervous system in the Theiler’s virus model of multiple sclerosis. J Neuroimmunol. 2011;232:35–40.
21. Lipton HL. Theiler’s virus infection in mice: an unusual biphasic disease process leading to demyelination. Infect Immun. 1975;11:147–55.
22. Tsuoda I, Kuang LQ, Libbey JE, Fujinami RS. Axonal injury heralds virus-induced demyelination. J Neuroimmunol. 2011;24:291–9.
23. McGavcn DB, Murray PD, Rehoreva Quiones C, Schmlzer JD, Low PA, Rodriguez M. Axon loss results in spinal cord atrophy, electrophysiological abnormalities and neurological deficits following demyelination in a chronic inflammatory model of multiple sclerosis. Brain. 2000;123-Part 3:519–31.
24. McGavcn DB, Murray PD, Rodriguez M. Quantification of spinal cord demyelination, remyelination, atrophy, and axonal loss in a model of progressive neurologic injury. J Neurosci Res. 1999;58:492–504.
25. Murray PD, McGavcn DB, Sathornsumetee S, Rodriguez M. Spontaneous remyelination following extensive demyelination is associated with improved neurological function in a viral model of multiple sclerosis. Brain. 2001;124:403–16.
26. Tsai SL, Sorensen EM. Evidence for viral etiology of multiple sclerosis. Semin Neurol. 2011; 31:207–16.
27. Serafini B, Rosicarelli B, Franciotta D, Maglizzi R, Reynolds R, Cinque P, Andreoni L, Trivedi P, Salvetti M, Faggionni A, Abosi F. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med. 2007;204:2899–912.
28. Gill F, Royce DB, Pachner AR. Measuring progressive neurological disability in a mouse model of multiple sclerosis. J Vis Exp. 2016.
29. Li L, Matsumoto M, Seabrook TJ, Cojic C, Brinkman V, Pachner AR. The effect of FTY720 in the Theiler’s virus model of multiple sclerosis. J Neurosci. 2011;30:8481–8.
30. Trotter M, Kallio P, Wang W, Lipton HL. High numbers of viral RNA copies in the central nervous system of mice during persistent infection with Theiler’s virus. J Virol. 2001;75:7420–8.
31. Gilli F, Royce DB, DiSano KD, Pachner AR. Pglypted interferon beta in the treatment of the Thielers murine encephalomyelitis virus mouse model of multiple sclerosis. J Neuroimmunol. 2017;313:34–40.

32. Gilli F, Li L, Royce DB, DiSano KD, Pachner AR. Treatment of Thielers virus-induced demyelinating disease with teriflunomide. J Neurovirol. 2017;23:825–38.

33. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(–Delta Delta C(T)) Method. Methods. 2001;25:402–8.

34. DiSano KD, Stohlman SA, Bergmann CC. Activated GLI(+) B cells are maintained within the inflamed CNS in the absence of follicle formation during viral encephalomyelitis. Brain Behav Immun. 2017;60:71–83.

35. Kucherov VK, Anderson AG, Waldner H, Munzer D, Bettelli E, Nicholson LB. T cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autophagogenic T cell repertoire. Annu Rev Immunol. 2002;20:101–23.

36. Legroux L, Atour N. Multiple sclerosis and T lymphocytes: an entangled story. J Neuroimmun Pharmacol. 2015;10:528–46.

37. Weimer H. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch Neurol. 2004;61:163–5.

38. Wekerle H. Multiple sclerosis and T lymphocytes: an entangled story. J Neuroimmune Pharmacol. 2015;10:528–46.

39. Michel L, Touil H, Piker NB, Sommerman JL, Prat A, Bar-Or A. B cells in the multiple sclerosis central nervous system: trafficking and contribution to CNS-compartmentalized inflammation. Front Immunol. 2015;6:636.

40. Oztalbas S, Cinar BP, Ozcelik P, Basar H, Kosehasanogullari G. Intrathecal IgM index correlates with a severe disease course in multiple sclerosis clinical and MRI results. Clin Neurol Neurosurg. 2017;160:27–9.

41. Izquierdo G, Angulo S, Garcia-Moreno JM, Gamero MA, Navarro G, Gata JM. Parker Harp CR, Archambault AS, Sim J, Ferris ST, Mikesell RJ, Koni PA, Joseph FG, Hirst CL, Pickersgill TP, Ben-Shlomo Y, Robertson NP, Scolding NJ, Connor RA, Anderton SM, Bar-Or A, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. Curr Opin Immunol. 2008;20:332–8.

42. Izquierdo G, Angulo S, Garcia-Moreno JM, Gamero MA, Navarro G, Gata JM. Parker Harp CR, Archambault AS, Sim J, Ferris ST, Mikesell RJ, Koni PA, Joseph FG, Hirst CL, Pickersgill TP, Ben-Shlomo Y, Robertson NP, Scolding NJ, Connor RA, Anderton SM, Bar-Or A, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. Curr Opin Immunol. 2008;20:332–8.

43. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(–Delta Delta C(T)) Method. Methods. 2001;25:402–8.

44. Pierson ER, Stromnes IM, Goverman JM. B cells promote induction of experimental autoimmune encephalomyelitis (EAE) in vivo. J Exp Med. 2012;209:1001–10.

45. Lund FE. Cytokine-producing B lymphocytes-key regulators of immunity. Curr Opin Immunol. 2008;20:332–8.

46. Maeda D, Smith SH, DiLillo DJ, Bryant JM, Candando KM, Weaver CT, Tedder TF. Regulatory B10 cells differentiate into antibody-secreting cells after transient IL-10 production in vivo. J Immunol. 2012;188:1036–48.

47. Shen P, Roeh T, Lampropoulou V, OConnor RA, Sterven U, Hilgenberg E, Ries S, Dang VD, Jaimes Y, Davison C, et al. IL-35-producing B cells are critical regulators of immunity during autoimmunity and infectious diseases. Nature. 2014;507:366–70.